View Older Stories View More Recent Stories
-
BofA Adjusts US 1 List
-
Eli Lilly & Co. (LLY) call put ratio 2.1 calls to 1 put
-
BofA Securities Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Lowered to $973 at Guggenheim
-
Eli Lilly & Co. (LLY) Announces FDA Approval of Omvoh for Crohn's disease
-
Bernstein SocGen Group Reiterates Outperform Rating on Eli Lilly (LLY) Despite 'Disappointing' GLP-1 Miss
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Wells Fargo Reiterates Overweight Rating on Eli Lilly (LLY)
-
BofA Securities on Eli Lilly (LLY): 'a particularly good buying opportunity'
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put as share price pulls back
-
Lilly (LLY) provides update on 2024 revenue guidance, announces 2025 revenue guidance
-
Eli Lilly & Co. (LLY) Asks Biden Administration to Pause Drug-price Negotiation - Bloomberg
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Lilly (LLY) to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
-
Eli Lilly (LLY) in advanced talks to buy US cancer biotech for up to $2.5bn - FT
-
Medicare can now cover Eli Lilly’s (LLY) Zepbound for sleep apnea, CMS says - CNBC
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY); ' Near-term, It's All About GLP-1/Obesity'
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Eli Lilly & Co. (LLY) commends ITC ruling cracking down on the unlawful importation and sale of knock-off tirzepatide products that put Americans at risk
-
Piper Sandler on HGNS Devices Following Eli Lilly's Zepbound FDA Indication Approval
-
KeyBanc Weighs in on GLP-1 Injection Leaders Following Latest NVO Results
-
Eli Lilly & Co. (LLY) call put ratio 1.8 calls to 1 put after Novo Nordisk (NVO) released Cagrisema data
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
Viking Therapeutics (VKTX), Others Gain After Novo Nordisk (NVO) Data Falls Short of Expectations
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY); 'Lilly's Tirzepatide is Officially "No Longer in Shortage"'
-
Eli Lilly & Co. (LLY) option IV bid into end of year
-
Hims & Hers Health (HIMS) Quickly Falls 9% after FDA Says the Obesity Drug Shortage Ended
-
Eli Lilly & Co. (LLY) Kisunla Approved in China for Treatment of Early Symptomatic Alzheimer's Disease
-
Eli Lilly & Co. (LLY) and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
-
Innovent and Eli Lilly Expand Collaboration
-
Ozempic Study Found Small Number Of Patients With Vision Loss - Bloomberg
-
Eli Lilly's (LLY) Omvoh recommended by CHMP for approval in EU
-
Bernstein: 'GLP-1s vs. the Weight of the World'
-
Bernstein Sees Eli Lilly (LLY) 'In a Strong Position to Work Creatively With the New Administration'
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Eli Lilly & Co. (LLY) Reports Imlunestrant Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio
-
Hims & Hers Health, Inc. (HIMS) falls 7% as Ro says it is working with Eli Lilly to streamline access to Zepbound
-
After-hours movers: Oracle, MongoDB, C3 AI, Lilly and more
-
Eli Lilly & Co. (LLY) Raises Quarterly Dividend 15.4% to $1.50; 0.7% Yield
-
Lilly (LLY) announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
-
Bernstein: 'Could the lion's share of China GLP-1 market go to domestic players?'
-
Lilly (LLY) announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin
-
Trump hosted the chief executives of Pfizer (PFE), Eli Lilly & Co. (LLY) - Axios
-
Zepbound vs Wegovy: 'Eli Lilly reinforces its (expected) superiority'
-
BMO Capital: Five Key BioPharma Catalysts Through Year-End '24
-
Eli Lilly & Co's (LLY) Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
-
Lilly Products Show Strength Heading Into the Holiday
-
Is Trump 2.0 good or bad for healthcare stocks?

